Background & aims In 2016, ESPEN published the guideline for Chronic Intestinal Failure
(CIF) in adults. An updated version of ESPEN guidelines on CIF due to benign disease in …

The advancement of precision medicine critically depends on the robustness and specificity
of the carriers used for the targeted delivery of effector molecules in the human body …

Abnormalities in the intestinal barrier are a possible cause of celiac disease (CD)
development. In animal studies, the positive effect of prebiotics on the improvement of gut …

Background and aims The glucagon-like peptide-2 (GLP-2) analogue, teduglutide, allows to
reduce the intravenous supplementation (IVS) dependency of patients with short bowel …

Colorectal carcinoma (CRC) is the third most frequent neoplasm worldwide and the second
leading cause of mortality. Neuroendocrine peptides such as glucagon, bombesin …

Background Teduglutide (TED) is a glucagon-like peptide 2 analogue approved in patients
with short bowel syndrome with chronic intestinal failure. Bowel epithelial hyperplasia has …

Nutrient sensing determines digestive and hormonal responses following nutrient ingestion.
We have previously reported decreased levels of glucagon‐like peptide 2 (GLP‐2) in …

Pediatric intestinal failure (IF) occurs in infants or children whose intestinal digestive and
absorptive function is insufficient to meet fluid, electrolyte, and nutrient requirements. 1 …

The recurrent pathological inflammation of the gut is a major concern in diabetic patients.
With the failure of anti-inflammatory or diabetic drugs to limit relapse of colon inflammation …

Short bowel syndrome (SBS) is the leading cause of intestinal failure (IF) in infants, and
occurs when there is a significant loss of intestine due to acquired or congenital reasons …